Cardiac Troponin I Microfluidic Chip Driven by Adaptive Pressure

To develop and design an adaptive microfluidic chip for accurate determination of cardiac troponin I (cTnI) in whole blood sample and explore the operating parameters of the chip in detecting cTnI, in order to provide a novel strategy for the detection of cTnI, cTnI microfluidic chip was prepared by injection moulding, and the improved polystyrene polymer was used as the chip substrate to construct a three-layer composite structure, namely the upper, middle, and lower layers. The antihuman troponin I antibody I/II was grafted onto the chip surface to construct the detection reaction zone using UV-induced production of surface-active free radicals. The stability of the chip preparation process, the running performance of the chip, and the analytical performance of the whole blood samples were investigated. It was shown that I adaptive pressure-driven microfluidic chip has the advantages of easy bonding, integration, and a simple and stable production process. In the actual detection and analysis, the chip has high selectivity for cTnI in whole blood, lower detection limit (0.054 ng/mL), and small difference between batches (RSD% 2.50%). Therefore, the chip is assumed to provide novel strategy for the assessment of myocardial infarction by detecting cTnI.

Download Full-text

Evaluation of Innotrac Aio! Second-Generation Cardiac Troponin I Assay: The Main Characteristics for Routine Clinical Use

Journal of Automated Methods and Management in Chemistry ◽

10.1155/jammc/2006/39325 ◽

2006 ◽

Vol 2006 ◽

pp. 1-7 ◽

Cited By ~ 4

Author(s):

P. Hedberg ◽

J. Valkama ◽

E. Suvanto ◽

S. Pikkujämsä ◽

K. Ylitalo ◽

...

Keyword(s):

Rheumatoid Factor ◽

Whole Blood ◽

Cardiac Troponin ◽

First Generation ◽

Second Generation ◽

Troponin I ◽

Reference Group ◽

Rapid Test ◽

Cardiac Troponin I ◽

The Stability

The availability of a simple, sensitive, and rapid test using whole blood to facilitate processing and to reduce the turnaround time could improve the management of patients presenting with chest pain. The aim of this study was an evaluation of the Innotrac Aio! second-generation cardiac troponin I (cTnI) assay. The Innotrac Aio! second-generation cTnI assay was compared with the Abbott AxSYM first-generation cTnI, Beckman Access AccuTnI, and Innotrac Aio! first-generation cTnI assays. We studied serum samples from 15 patients with positive rheumatoid factor but with no indication of myocardial infarction (MI). Additionally, the stability of the sample with different matrices and the influence of hemodialysis on the cTnI concentration were evaluated. Within-assay CVs were 3.2%–10.9%, and between-assay precision ranged from 4.0% to 17.2% for cTnI. The functional sensitivity(CV=20%)and the concentration giving CV of 10% were approximated to be 0.02 and 0.04, respectively. The assay was found to be linear within the tested range of 0.063–111.6μg/L. The correlations between the second-generation Innotrac Aio!, Access, and AxSYM cTnI assays were good (rcoefficients 0.947–0.966), but involved differences in the measured concentrations, and the biases were highest with cTnI at low concentrations. The second-generation Innotrac Aio! cTnI assay was found to be superior to the first-generation assay with regard to precision in the low concentration range. The stability of the cTnI level was best in the serum, lithium-heparin plasma, and lithium-heparin whole blood samples (n=10, decrease<10%in 24 hours at+20°Cand at+4°C. There was no remarkable influence of hemodialysis on the cTnI release. False-positive cTnI values occurred in the presence of very high rheumatoid factor values, that is, over 3000 U/L. The 99th percentile of the apparently healthy reference group was≤0.03 μg/L. The results demonstrate the very good analytical performance of the second-generation Innotrac Aio! cTnI assay.

Download Full-text

Degradation of Cardiac Troponin I in Serum Complicates Comparisons of Cardiac Troponin I Assays

Clinical Chemistry ◽

10.1093/clinchem/45.7.1018 ◽

1999 ◽

Vol 45 (7) ◽

pp. 1018-1025 ◽

Cited By ~ 61

Author(s):

Qinwei Shi ◽

Mingfu Ling ◽

Xiaochen Zhang ◽

Minyuan Zhang ◽

Lilly Kadijevic ◽

...

Keyword(s):

Western Blot ◽

Human Serum ◽

Cardiac Troponin ◽

Troponin I ◽

Cardiac Troponin I ◽

Stable Region ◽

Terminal Portion ◽

Key Factor ◽

The Stability ◽

Serum Cardiac Troponin

Abstract Background: Up to a 20-fold variation in serum cardiac troponin I (cTnI) concentration may be observed for a given patient sample with different analytical methods. Because more limited variation is seen for control materials and for purified cTnI, we explored the possibility that cTnI was present in altered forms in serum. Methods: We used four recombinantly engineered cTnI fragments to study the regions of cTnI recognized by the Stratus®, Opus®, and ACCESS® immunoassays. The stability of these regions in serum was analyzed with Western blot. Results: The measurement of several control materials and different forms of purified cTnI using selected commercial assays demonstrated five- to ninefold variation. Both the Stratus and Opus assays recognized the N-terminal portion (NTP) of cTnI, whereas the ACCESS assay recognized the C-terminal portion (CTP) of cTnI. Incubation of recombinant cTnI in normal human serum produced a marked decrease in cTnI concentration as determined with the ACCESS, but not the Stratus, immunoassay. Western blot analysis of the same samples using cTnI NTP- and CTP-specific antibodies demonstrated preferential degradation of the CTP of cTnI. Conclusions: The availability of serum cTnI epitopes is markedly affected by the extent of ligand degradation. The N-terminal half of the cTnI molecule was found to be the most stable region in human serum. Differential degradation of cTnI is a key factor in assay-to-assay variation.

Download Full-text

Single Drop Whole Blood Diagnostics: Portable Biomedical Sensor for Cardiac Troponin I Detection

Analytical Chemistry ◽

10.1021/acs.analchem.7b05018 ◽

2018 ◽

Vol 90 (4) ◽

pp. 2867-2874 ◽

Cited By ~ 20

Author(s):

Indu Sarangadharan ◽

Shin-Li Wang ◽

Revathi Sukesan ◽

Pei-chi Chen ◽

Tze-Yu Dai ◽

...

Keyword(s):

Whole Blood ◽

Cardiac Troponin ◽

Troponin I ◽

Cardiac Troponin I ◽

Single Drop ◽

Biomedical Sensor

Download Full-text

Evaluation of a Rapid Bedside Immunochromatographic Assay for Detection of Cardiac Troponin I in Whole Blood

Clinical Chemistry and Laboratory Medicine (CCLM) ◽

10.1515/cclm.2001.073 ◽

2001 ◽

Vol 39 (5) ◽

Cited By ~ 4

Author(s):

Franca Pagani ◽

Cristina Serena ◽

Carla Bosio ◽

Claudio Cuccia ◽

Mauro Panteghini

Keyword(s):

Whole Blood ◽

Cardiac Troponin ◽

Troponin I ◽

Cardiac Troponin I ◽

Immunochromatographic Assay

Download Full-text

Simultaneous Rapid Measurement of Whole Blood Myoglobin, Creatine Kinase MB, and Cardiac Troponin I by the Triage Cardiac Panel for Detection of Myocardial Infarction

Clinical Chemistry ◽

10.1093/clinchem/45.2.199 ◽

1999 ◽

Vol 45 (2) ◽

pp. 199-205 ◽

Cited By ~ 125

Author(s):

Fred S Apple ◽

Robert H Christenson ◽

Roland Valdes ◽

Alexander J Andriak ◽

Amy Berg ◽

...

Keyword(s):

Myocardial Infarction ◽

Creatine Kinase ◽

Whole Blood ◽

Cardiac Troponin ◽

Troponin I ◽

Point Of Care ◽

Cardiac Troponin I ◽

Clinical Sensitivity ◽

Creatine Kinase Mb ◽

Acute Mi

Abstract This multicenter study evaluated the Biosite Triage® Cardiac Panel as a quantitative, multimarker, whole blood system for the detection of acute myocardial infarction (MI). Optimum cutoffs for the discrimination of acute MI (n = 192 patients, 59 with MI) as determined by ROC curve analyses were as follows: 0.4 μg/L for cardiac troponin I (cTnI); 4.3 μg/L for the creatine kinase MB isoenzyme (CK-MB); and 107 μg/L for myoglobin. The Triage Panel showed the following concordances for detection or rule-out of MI compared with established devices: cTnI >89%; CK-MB >81%; myoglobin >69%. No significant differences were present between methods for the same marker. Diagnostic efficiencies demonstrated comparable sensitivities and specificities for the diagnosis of MI in patients presenting with symptoms compared with the Dade, Beckman, and Behring CK-MB, cTnI, and myoglobin assays; the ratio of sensitivity to specificity for each marker was as follows: cTnI, 98%:100%; CK-MB, 95%:91%; myoglobin, 81%:92%. The areas under the ROC curves for the Biosite myoglobin, CK-MB, and cTnI were 0.818, 0.905, and 0.970, respectively; the areas were significantly different, P <0.05. In patients with skeletal muscle injury and renal disease, the Triage cTnI showed 94% and 100% specificity, respectively. The Triage panel offers clinicians a whole blood, point-of-care analysis of multiple cardiac markers that provides excellent clinical sensitivity and specificity for the detection of acute MI.

Download Full-text

Evaluation of a novel high sensitivity cardiac troponin I assay with whole blood

Clinica Chimica Acta ◽

10.1016/j.cca.2020.05.036 ◽

2020 ◽

Vol 508 ◽

pp. 273-276

Author(s):

Ya-hui Lin ◽

Yang Li ◽

Bao-man Su ◽

Jin-suo Kang ◽

Zhou Zhou

Keyword(s):

Whole Blood ◽

Cardiac Troponin ◽

Troponin I ◽

High Sensitivity ◽

Cardiac Troponin I

Download Full-text

Electrospun TiO2 nanofiber integrated lab-on-a-disc for ultrasensitive protein detection from whole blood

Lab on a Chip ◽

10.1039/c4lc00900b ◽

2015 ◽

Vol 15 (2) ◽

pp. 478-485 ◽

Cited By ~ 26

Author(s):

Won Seok Lee ◽

Vijaya Sunkara ◽

Ja-Ryoung Han ◽

Yang-Seok Park ◽

Yoon-Kyoung Cho

Keyword(s):

Whole Blood ◽

Cardiac Troponin ◽

Troponin I ◽

Protein Detection ◽

Cardiac Troponin I ◽

Tio2 Nanofiber

From 10 μL of whole blood, full steps of an ELISA are automated to achieve femtomolar- and picomolar-level detection for C-reactive proteins and cardiac troponin I, respectively.

Download Full-text